Related Experiment Videos
An update on chronic myeloid leukaemia
1School of Clinical Science, Department of Haematology University of Newcastle, Newcastle upon Tyne, UK.
Clinical Medicine (London, England)
|November 15, 2001
Summary
The therapy for chronic myeloid leukemia (CML) is evolving. Early results for STI571 show promise, with this new treatment expected to become available soon.
Area of Science:
- Oncology
- Hematology
Background:
- Chronic myeloid leukemia (CML) therapy is an evolving field.
- Long-term data for STI571 treatment in CML patients are pending.
Purpose of the Study:
- To summarize current therapeutic considerations for CML.
- To highlight the importance of patient awareness regarding treatment options, risks, and benefits.
Main Methods:
- Review of current therapeutic strategies for CML.
- Consideration of emerging treatments like STI571.
Main Results:
- Preliminary results for STI571 are encouraging.
- STI571 is anticipated for licensing in late 2001/early 2002.
Conclusions:
- STI571 is expected to play a significant role in CML treatment.
- Patient-centered decision-making, considering individual circumstances and preferences, is crucial when evidence for treatment superiority is limited.